Investors sue Teva over $41B Actavis deal

Teva Pharmaceuticals (NYSE:TEVA) and a handful of current and former executives were hit with a lawsuit yesterday alleging that the drugmaker hid the negative fallout linked to its $40.5 billion purchase of Actavis Generics.

Barry Baker, a Teva investor, claimed that the company, former CEO Erez Vigodman, ex-CFO Eyal Desheh and interim CEO Yitzhak Peterburg issued false and misleading statements after the acquisition which caused shares in Teva to trade at artificially high levels.

Get the full story at our sister site, Drug Delivery Business News.

The post Investors sue Teva over $41B Actavis deal appeared first on MassDevice.

from MassDevice http://ift.tt/2wllezK